Our management team represents decades of experience and expertise in biomedical product R&D, regulatory and clinical affairs, GMP compliant manufacturing, international business, and global marketing.
Michael B. Jebsen
Chief Financial Officer, Interim Chief Executive Officer & President
Mr. Jebsen was named Interim Chief Executive Officer in August 2011, while retaining his role as Chief Financial Officer and Treasurer. He joined Oxygen as our Accounting Manager in April 2009 and was elected CFO in August 2009. Before joining Oxygen, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, he held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a certified Public Accountant, licensed in North Carolina.
EVP Clinical Development
Dr. Bradshaw is a biochemist, by training, with a diverse background that includes preclinical experience in the areas of drug metabolism and pharmacology. His scientific interests migrated into the area of clinical development while at GSK in the late nineties and since that time he has held clinical project management positions of increasing responsibility. Since joining the company in August of 2010, he has been instrumental in guiding the traumatic brain injury trial to a successful conclusion for the first cohort. Dr. Bradshaw earned his BA in Chemistry from Erskine College and a Ph.D. in Biochemistry from the University of South Carolina.
SVP, Legal Affairs, General Council, and Corporate Secretary
Ms. Hecox joined Oxygen as General Counsel in October 2009. She brings over a decade of experience in the pharmaceutical/biotech industry from prior positions with Becton Dickinson, eTrials Worldwide, Quintiles, and DSM Pharmaceuticals. Ms. Hecox holds a BS degree in Communications from the State University of New York and an MBA from East Carolina University. She received her JD degree from North Carolina Central University, graduating cum laude, and is admitted to the North Carolina State Bar.
Ellen T. Corliss
SVP, Corporate Communications and Investor Relations
Ms. Corliss joined Oxygen as Vice President of Corporate Communications and Investor Relations in March 2010. Previously she was Vice President of Corporate Communications and Investor Relations at Embrex, Inc., which was later acquired by Pfizer. Throughout her career, Ms. Corliss has provided communications counsel to numerous biotechnology companies in the pre- and post IPO phase. Ms. Corliss holds a BA in Political Science from Tufts University where she also studied journalism extensively.